Departments of Pharmaceutics (G.Z., N.I.) and Medicinal Chemistry (D.O., A.N.), School of Pharmacy, and Department of Biochemistry, School of Medicine (A.Z.), University of Washington, Seattle, Washington.
Departments of Pharmaceutics (G.Z., N.I.) and Medicinal Chemistry (D.O., A.N.), School of Pharmacy, and Department of Biochemistry, School of Medicine (A.Z.), University of Washington, Seattle, Washington
Mol Pharmacol. 2018 May;93(5):489-503. doi: 10.1124/mol.117.111039. Epub 2018 Feb 23.
The clearance of retinoic acid (RA) and its metabolites is believed to be regulated by the CYP26 enzymes, but the specific roles of CYP26A1, CYP26B1, and CYP26C1 in clearing active vitamin A metabolites have not been defined. The goal of this study was to establish the substrate specificity of CYP26C1, and determine whether CYP26C1 interacts with cellular retinoic acid binding proteins (CRABPs). CYP26C1 was found to effectively metabolize all- retinoic acid (RA), 9--retinoic acid (9--RA), 13--retinoic acid, and 4-oxo-RA with the highest intrinsic clearance toward 9--RA. In comparison with CYP26A1 and CYP26B1, CYP26C1 resulted in a different metabolite profile for retinoids, suggesting differences in the active-site structure of CYP26C1 compared with other CYP26s. Homology modeling of CYP26C1 suggested that this is attributable to the distinct binding orientation of retinoids within the CYP26C1 active site. In comparison with other CYP26 family members, CYP26C1 was up to 10-fold more efficient in clearing 4-oxo-RA (intrinsic clearance 153 l/min/pmol) than CYP26A1 and CYP26B1, suggesting that CYP26C1 may be important in clearing this active retinoid. In support of this, CRABPs delivered 4-oxo-RA and RA for metabolism by CYP26C1. Despite the tight binding of 4-oxo-RA and RA with CRABPs, the apparent Michaelis-Menten constant in biological matrix () value of these substrates with CYP26C1 was not increased when the substrates were bound with CRABPs, in contrast to what is predicted by free drug hypothesis. Together these findings suggest that CYP26C1 is a 4-oxo-RA hydroxylase and may be important in regulating the concentrations of this active retinoid in human tissues.
视黄酸(RA)及其代谢物的清除被认为受 CYP26 酶调节,但 CYP26A1、CYP26B1 和 CYP26C1 在清除活性维生素 A 代谢物方面的具体作用尚未确定。本研究的目的是确定 CYP26C1 的底物特异性,并确定 CYP26C1 是否与细胞视黄酸结合蛋白(CRABP)相互作用。研究发现 CYP26C1 能有效代谢全反式视黄酸(RA)、9--视黄酸(9--RA)、13--视黄酸和 4-氧代-RA,对 9--RA 的内在清除率最高。与 CYP26A1 和 CYP26B1 相比,CYP26C1 导致视黄醇代谢产物谱不同,提示 CYP26C1 的活性部位结构与其他 CYP26 不同。CYP26C1 的同源建模表明,这归因于视黄醇在 CYP26C1 活性部位的独特结合取向。与其他 CYP26 家族成员相比,CYP26C1 清除 4-氧代-RA 的效率高达 10 倍(内在清除率 153 l/min/pmol),高于 CYP26A1 和 CYP26B1,表明 CYP26C1 可能在清除这种活性视黄醇方面很重要。支持这一观点的是,CRABP 将 4-氧代-RA 和 RA 递送给 CYP26C1 进行代谢。尽管 4-氧代-RA 和 RA 与 CRABP 紧密结合,但当这些底物与 CRABP 结合时,它们与 CYP26C1 的表观米氏常数()值并没有增加,这与游离药物假说所预测的相反。这些发现表明 CYP26C1 是 4-氧代-RA 羟化酶,可能在调节人组织中这种活性视黄醇的浓度方面很重要。